A joint venture of the divisions of Chemistry and Chemical Engineering and Biology and Biological Engineering, Caltech's graduate degree option combines the disciplines of biochemistry and molecular biophysics, enabling degree candidates to explore biological processes at the molecular scale. Combined with an existing Amgen one-year fellowship and $3.75 million from Caltech's Gordon and Betty Moore Graduate Fellowship Match, the gift will endow two-year fellowships for eight students — the number, on average, who enroll in Caltech's graduate program in biochemistry and molecular biology (BMB).
The fellowship program will be named in honor of Caltech president emeritus David Baltimore, whose research revealed connections among viruses, the immune system, genes, and diseases such as cancer and AIDS. In 1975, Baltimore received the Nobel Prize in Physiology or Medicine for his work on the genetic mechanisms of viruses.
"This exciting new program represents the latest step forward in our company's long-standing partnership with Caltech," said Amgen chair and CEO Robert Bradway. "It is fitting that this program bears the name of David Baltimore, Amgen’s long-serving former board colleague and collaborator. I'm confident that the Amgen Foundation's commitment to advancing the future of scientific innovation will be strengthened through our support of some of today’s most promising young researchers."